Global Hemophilia Market - 2023-2030
Description
Global Hemophilia Market - 2023-2030
The Global Hemophilia Market reached USD 11.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 18 billion by 2030. The Hemophilia Market is expected to exhibit a CAGR of 5.9% during the forecast period 2023-2030.
A spectrum of conditions impacting the body's blood clotting function is comprehended as bleeding disorders. Heeding an injury, multiple disorders can induce extreme and prolonged bleeding. Many bleeding conditions are inherited, although some are induced because of liver conditions, medication side effects, low red blood cell count, vitamin K deficiency, and additional elements.
Market Dynamics
The growing number of hemophilia cases drives the Global Hemophilia Market in the forecast period.
The growing prevalence of hemophilia is driving the global hemophilia market growth during the forecast period. For instance, according to the Hemophilia Federation of America, more than 1.1 million individuals globally live with hemophilia, and approximately 30,000 are in the United States. All races and economic classes are impacted equally.
The increasing government initiatives and funding provide the global hemophilia market with future growth opportunities.
The different initiatives and funding by various organizations present the global hemophilia market with prospective growth opportunities in the upcoming years. For instance, in March 2022, the National Heart, Lung, and Blood Institute provided funding of USD 12 million to an Indiana University School of Medicine researcher who will lead a multi-institute action to design hemophilia treatments.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine War Impact Analysis
The Russia-Ukraine war had a negative influence on the market because of the conflict, patients from Ukraine and neighboring provinces could not receive care; however, various organizations stood up and tried to help the individuals.
For instance, the World Federation of Hemophilia teams is closely monitoring the situation to support best those who are affected via cooperating with national member organizations (NMOs), hemophilia treatment centers (HTCs), and additional stakeholders in Ukraine and neighboring nations that are influenced by the dispute.
Additionally, Russia and Ukraine are regarded as clinical trial hubs of the world, and this current circumstance is impeding the clinical research projects in these regions, thus negatively influencing the global hemophilia market growth.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession.
Artificial Intelligence Impact Analysis
AI is largely utilized in designing and developing new treatment options for hemophilia, positively impacting the Global Hemophilia Market growth in the forthcoming years. For instance, the Duke University Durham, NC projects considered for Pfizer funding will concentrate on employing Machine Learning/Artificial Intelligence in developing treatments with an emphasis on arising potential one-time therapies like genetic medicine/gene transfer.
Segment Analysis
The Global Hemophilia Market is segmented based on disease type, product type, therapy, and region.
The gene therapy segment is estimated to hold a global market share by 2030.
The segment is estimated to hold around 35.9% of the Global Hemophilia Market by 2030 due to the increased funding and investments in gene therapy for hemophilia. For instance, Amarna Therapeutics, a privately held European biotechnology company, received €5 million (approximately $5.6 million) in new funding, which it intends to utilize for developing its lead development, AMA005, an investigational gene treatment that seeks to correct blood clotting in individuals with hemophilia B.
Geographical Analysis
Europe is estimated to hold the 2nd largest share of the Global Hemophilia Market during the forecast period.
The market developments such as mergers, acquisitions, product launches, product approvals, and collaborations, and the Europe region is estimated to hold around 28.7% of the total global hemophilia market by 2030. For instance, in September 2022, Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, acquired Forma Therapeutics, Holdings, a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders.
Competitive Landscape
The major global players in the market include Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion S.p.A, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), and Takeda Pharmaceutical (Shire Plc.), Grifols among others.
Why Purchase the Report?
• To visualize the Global Hemophilia Market segmentation based on disease type, product type, therapy, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hemophilia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Hemophilia Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
195 Pages
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Disease Type
- 3.2. Snippet by Product Type
- 3.3. Snippet by Therapy
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Research Activities
- 4.1.1.2. Growing Prevalence
- 4.1.2. Restraints
- 4.1.2.1. High Treatment Costs
- 4.1.3. Opportunity
- 4.1.4. Government Initiatives
- 4.1.5. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Regulatory Analysis
- 5.3. Pricing Analysis
- 5.4. Patent Analysis
- 5.5. Epidemiology Analysis
- 5.6. Reimbursement Scenarios
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine War Analysis
- 8. Global Recession Analysis
- 9. Artificial Intelligence Impact Analysis
- 10. By Disease Type
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 10.1.2. Market Attractiveness Index, By Disease Type
- 10.2. Hemophilia A
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Hemophilia B
- 10.4. Others
- 11. By Product Type
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.1.2. Market Attractiveness Index, By Product Type
- 11.2. Recombinant Coagulation *
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Factor Concentrates
- 11.4. Plasma-derived Coagulation
- 11.5. Other
- 12. By Therapy
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 12.1.2. Market Attractiveness Index, By Therapy
- 12.2. Replacement Therapy
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Gene Therapy
- 12.4. Immune Tolerance Induction Therapy
- 13. By Region
- 13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
- 13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.2.6.1. The U.S.
- 13.2.6.2. Canada
- 13.2.6.3. Mexico
- 13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.3.6.1. Germany
- 13.3.6.2. The U.K.
- 13.3.6.3. France
- 13.3.6.4. Italy
- 13.3.6.5. Spain
- 13.3.6.6. Rest of Europe
- 13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.4.6.1. Brazil
- 13.4.6.2. Argentina
- 13.4.6.3. Rest of South America
- 13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.5.6.1. China
- 13.5.6.2. India
- 13.5.6.3. Japan
- 13.5.6.4. Australia
- 13.5.6.5. Rest of Asia-Pacific
- 13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 14. Competitive Landscape
- 14.1. Competitive Scenario
- 14.2. Market Share Analysis
- 14.3. Mergers and Acquisitions Analysis
- 15. Company Profiles
- 15.1. Bayer AG
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
- 15.2. BioMarin Pharmaceutical, Inc.
- 15.3. CSL Behring
- 15.4. Kedrion S.p.A
- 15.5. Novo Nordisk
- 15.6. Pfizer, Inc.
- 15.7. Roche (Chugai Pharmaceutical Co.)
- 15.8. Sanofi (Genzyme Corporation)
- 15.9. Takeda Pharmaceutical (Shire Plc.)
- 15.10. Octapharma
- LIST NOT EXHAUSTIVE
- 16. Appendix
- 16.1. About Us and Services
- 16.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
